ASCO: Merck KGaA's Bavencio combo misses survival mark in RCC
Although the overall survival miss won't cost Bavencio its FDA approval, it puts the drug further behind rival PD-1 combos from Merck & Co. and BMS.
Source: fiercepharma.com
Keytruda Lenvima News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Keytruda Lenvima. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Keytruda Lenvima Today - Breaking & Trending Today
Merck/Eisai's Cancer Combo Therapy Ambition Dashed Once Again, Companies Throw Towel On Head & Neck Trial - Merck & Co (NYSE:MRK), Eisai Co (OTC:ESALF)
Merck & Co Inc (NYSE: MRK) and Eisai Ltd (OTC: ESALY) provided an update on the Phase 3 LEAP-010 trial evaluating Keytruda (pembrolizumab), plus Lenvima for recurrent or metastatic head and neck squamous c
Source: benzinga.com
Keytruda/Lenvima Trials Stop Due to Lack of Benefit
Two clinical trials investigating Keytruda plus Lenvima will be discontinued after the drug duo was not superior to other regimens for melanoma and colorectal cancer subsets.
Source: curetoday.com
Merck, Eisai's Keytruda plus Lenvima combo hits the mark in renal cancer
Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer Combination treatment topped Pfizer's Sutent in phase 3 Merck & Co/MSD and Eisai’s Keytruda plus Lenvima combination has scored positive top-line results from a phase 3 trial in advanced renal cell carcinoma (a form of kidney cancer). The results, from the KEYNOTE-581/CLEAR trial, demonstrated that Keytruda (pembrolizumab) and Lenvima (lenvatinib) met the primary endpoint of improved progression-free survival (PFS) compared to Pfizer’s Sutent (sunitinib) in first-line advanced renal cell carcinoma (RCC) patients. ...
Source: pmlive.com